Crystal Structure of the Cyclostreptin-Tubulin Adduct: Implications for Tubulin Activation by Taxane-Site Ligands.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
20 Mar 2019
Historique:
received: 28 02 2019
revised: 14 03 2019
accepted: 15 03 2019
entrez: 23 3 2019
pubmed: 23 3 2019
medline: 13 7 2019
Statut: epublish

Résumé

It has been proposed that one of the mechanisms of taxane-site ligand-mediated tubulin activation is modulation of the structure of a switch element (the M-loop) from a disordered form in dimeric tubulin to a folded helical structure in microtubules. Here, we used covalent taxane-site ligands, including cyclostreptin, to gain further insight into this mechanism. The crystal structure of cyclostreptin-bound tubulin reveals covalent binding to βHis229, but no stabilization of the M-loop. The capacity of cyclostreptin to induce microtubule assembly compared to other covalent taxane-site agents demonstrates that the induction of tubulin assembly is not strictly dependent on M-loop stabilization. We further demonstrate that most covalent taxane-site ligands are able to partially overcome drug resistance mediated by βIII-tubulin (βIII) overexpression in HeLa cells, and compare their activities to pironetin, an interfacial covalent inhibitor of tubulin assembly that displays invariant growth inhibition in these cells. Our findings suggest a relationship between a diminished interaction of taxane-site ligands with βIII-tubulin and βIII tubulin-mediated drug resistance. This supports the idea that overexpression of βIII increases microtubule dynamicity by counteracting the enhanced microtubule stability promoted by covalent taxane-site binding ligands.

Identifiants

pubmed: 30897704
pii: ijms20061392
doi: 10.3390/ijms20061392
pmc: PMC6471726
pii:
doi:

Substances chimiques

FR 182877 0
Polycyclic Compounds 0
Taxoids 0
Tubulin 0
Edetic Acid 9G34HU7RV0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : BFU2016-75319-R
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España
ID : RYC-2011-07900
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 31003A_166608
Organisme : National Institutes of Health
ID : CA121138
Organisme : European Cooperation in Science and Technology
ID : CM1407

Références

Br J Cancer. 1999 Jun;80(7):1020-5
pubmed: 10362110
J Biol Chem. 2000 Aug 25;275(34):26265-76
pubmed: 10818101
Curr Opin Oncol. 2000 Sep;12(5):450-8
pubmed: 10975553
J Biol Chem. 2003 Mar 7;278(10):8407-19
pubmed: 12496245
J Am Chem Soc. 2003 May 7;125(18):5393-407
pubmed: 12720453
Proc Natl Acad Sci U S A. 2003 May 27;100(11):6394-7
pubmed: 12740436
Cell Motil Cytoskeleton. 2003 Sep;56(1):45-56
pubmed: 12905530
Nature. 2004 Mar 11;428(6979):198-202
pubmed: 15014504
Chem Biol. 2004 Feb;11(2):225-36
pubmed: 15123284
J Biol Chem. 2005 Feb 4;280(5):3928-37
pubmed: 15550392
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Clin Cancer Res. 2005 Jan 1;11(1):298-305
pubmed: 15671559
J Biol Chem. 2005 Apr 1;280(13):12902-7
pubmed: 15695826
Biochemistry. 2005 Aug 30;44(34):11525-38
pubmed: 16114889
Chem Biol. 2005 Dec;12(12):1269-79
pubmed: 16356844
Nat Chem Biol. 2007 Feb;3(2):117-25
pubmed: 17206139
Methods Mol Med. 2007;137:245-60
pubmed: 18085234
Gene. 2008 Feb 15;409(1-2):100-8
pubmed: 18178340
Cell Motil Cytoskeleton. 2008 Jun;65(6):476-86
pubmed: 18435451
Mol Cancer Ther. 2008 Jul;7(7):2070-9
pubmed: 18645017
Cancer Res. 2008 Nov 1;68(21):8881-8
pubmed: 18974132
J Cell Physiol. 2009 Dec;221(3):505-13
pubmed: 19650075
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Nat Rev Cancer. 2010 Mar;10(3):194-204
pubmed: 20147901
Cancer Res. 2010 Jun 15;70(12):4995-5003
pubmed: 20501838
Eur J Med Chem. 2011 May;46(5):1630-7
pubmed: 21396747
ACS Chem Biol. 2011 Aug 19;6(8):789-99
pubmed: 21539341
PLoS One. 2011;6(6):e21717
pubmed: 21738778
J Mol Biol. 2011 Sep 9;412(1):35-42
pubmed: 21787788
Biochemistry. 2012 Jan 10;51(1):329-41
pubmed: 22148836
Chem Biol. 2012 Jun 22;19(6):686-98
pubmed: 22726683
Science. 2013 Feb 1;339(6119):587-90
pubmed: 23287720
J Cell Biol. 2013 Feb 4;200(3):259-70
pubmed: 23358242
J Clin Oncol. 1990 Jul;8(7):1207-16
pubmed: 2358837
Cancer Lett. 2013 Dec 1;341(2):214-23
pubmed: 23941826
Cancer Res. 2013 Nov 15;73(22):6780-92
pubmed: 24048820
Angew Chem Int Ed Engl. 2014 Feb 3;53(6):1621-5
pubmed: 24470331
J Mol Biol. 2014 Apr 17;426(8):1848-60
pubmed: 24530796
Bioorg Med Chem. 2014 Sep 15;22(18):5078-90
pubmed: 25047938
Bioorg Med Chem Lett. 2014 Dec 1;24(23):5357-63
pubmed: 25455482
PLoS One. 2015 Jun 08;10(6):e0129168
pubmed: 26052950
BMC Cancer. 2015 Jul 23;15:536
pubmed: 26198101
Invest New Drugs. 2016 Feb;34(1):129-37
pubmed: 26686345
Nat Commun. 2016 Jun 30;7:12103
pubmed: 27357539
J Mol Biol. 2016 Jul 31;428(15):2981-8
pubmed: 27395016
Nature. 2016 Nov 24;539(7630):579-582
pubmed: 27775717
J Mol Biol. 2017 Mar 10;429(5):633-646
pubmed: 28104363
Chembiochem. 2017 May 18;18(10):905-909
pubmed: 28207984
Int J Mol Sci. 2017 May 03;18(5):null
pubmed: 28467385
Cell Chem Biol. 2017 Jun 22;24(6):737-750.e6
pubmed: 28579361
Nat Commun. 2017 Jun 06;8:15787
pubmed: 28585532
Eur J Med Chem. 2017 Sep 8;137:488-503
pubmed: 28624703
J Nat Prod. 2018 Mar 23;81(3):494-505
pubmed: 29023132
Lancet Oncol. 2018 Jan;19(1):76-86
pubmed: 29248236
Hum Pathol. 2018 Apr;74:92-98
pubmed: 29339176
ACS Omega. 2016 Dec 31;1(6):1192-1204
pubmed: 30023505
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Lancet. 1995 Jul 1;346(8966):26-8
pubmed: 7603142
Biochemistry. 1993 Mar 23;32(11):2747-55
pubmed: 8096151
Biochemistry. 1993 Sep 28;32(38):10067-77
pubmed: 8104479
Nature. 1998 Jan 8;391(6663):199-203
pubmed: 9428769
Cell. 1999 Jan 8;96(1):79-88
pubmed: 9989499

Auteurs

Francisco de Asís Balaguer (FA)

Structural and Chemical Biology Department. Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain. pacobal@cib.csic.es.

Tobias Mühlethaler (T)

Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland. tobias.muehlethaler@psi.ch.

Juan Estévez-Gallego (J)

Structural and Chemical Biology Department. Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain. jeg@cib.csic.es.

Enrique Calvo (E)

Unidad de Proteómica. Centro Nacional de Investigaciones Cardiovasculares, CNIC. Melchor Fernández de Almagro 3, 28029 Madrid, Spain. ecalvo@cnic.es.

Juan Francisco Giménez-Abián (JF)

Structural and Chemical Biology Department. Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain. gimenezjf@cib.csic.es.

April L Risinger (AL)

Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA. risingera@uthscsa.edu.

Erik J Sorensen (EJ)

Department of Chemistry, Princeton University, Princeton, NJ 08544, USA. ejs@princeton.edu.

Christopher D Vanderwal (CD)

Department of Chemistry, 1102 Natural Sciences II, University of California, Irvine, CA 92697-2025, USA. cdv@uci.edu.

Karl-Heinz Altmann (KH)

ETH Zürich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, 8093 Zürich, Switzerland. karl-heinz.altmann@pharma.ethz.ch.

Susan L Mooberry (SL)

Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA. mooberry@uthscsa.edu.

Michel O Steinmetz (MO)

Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland. michel.steinmetz@psi.ch.
University of Basel, Biozentrum, 4056 Basel, Switzerland. michel.steinmetz@psi.ch.

María Ángela Oliva (MÁ)

Structural and Chemical Biology Department. Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain. marian@cib.csic.es.

Andrea E Prota (AE)

Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland. andrea.prota@psi.ch.

J Fernando Díaz (JF)

Structural and Chemical Biology Department. Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain. fer@cib.csic.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH